Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 38

1.

Is cannabidiol the ideal drug to treat non-motor Parkinson's disease symptoms?

Crippa JAS, Hallak JEC, Zuardi AW, Guimarães FS, Tumas V, Dos Santos RG.

Eur Arch Psychiatry Clin Neurosci. 2019 Jan 31. doi: 10.1007/s00406-019-00982-6. [Epub ahead of print] Review.

PMID:
30706171
2.

Cannabis Therapeutics and the Future of Neurology.

Russo EB.

Front Integr Neurosci. 2018 Oct 18;12:51. doi: 10.3389/fnint.2018.00051. eCollection 2018.

3.

Medical Use of Cannabinoids.

Fraguas-Sánchez AI, Torres-Suárez AI.

Drugs. 2018 Nov;78(16):1665-1703. doi: 10.1007/s40265-018-0996-1. Review.

PMID:
30374797
4.

Cannabidiol enhances morphine antinociception, diminishes NMDA-mediated seizures and reduces stroke damage via the sigma 1 receptor.

Rodríguez-Muñoz M, Onetti Y, Cortés-Montero E, Garzón J, Sánchez-Blázquez P.

Mol Brain. 2018 Sep 17;11(1):51. doi: 10.1186/s13041-018-0395-2.

5.

A Brief Background on Cannabis: From Plant to Medical Indications.

Klumpers LE, Thacker DL.

J AOAC Int. 2018 Aug 23. doi: 10.5740/jaoacint.18-0208. [Epub ahead of print]

PMID:
30139415
6.

Evidence for the use of "medical marijuana" in psychiatric and neurologic disorders.

Noel C.

Ment Health Clin. 2018 Mar 23;7(1):29-38. doi: 10.9740/mhc.2017.01.029. eCollection 2017 Jan.

7.

GPR3, GPR6, and GPR12 as novel molecular targets: their biological functions and interaction with cannabidiol.

Laun AS, Shrader SH, Brown KJ, Song ZH.

Acta Pharmacol Sin. 2019 Mar;40(3):300-308. doi: 10.1038/s41401-018-0031-9. Epub 2018 Jun 25. Review.

PMID:
29941868
8.

Cannabidiol as a Promising Strategy to Treat and Prevent Movement Disorders?

Peres FF, Lima AC, Hallak JEC, Crippa JA, Silva RH, Abílio VC.

Front Pharmacol. 2018 May 11;9:482. doi: 10.3389/fphar.2018.00482. eCollection 2018. Review.

9.

Review of the neurological benefits of phytocannabinoids.

Maroon J, Bost J.

Surg Neurol Int. 2018 Apr 26;9:91. doi: 10.4103/sni.sni_45_18. eCollection 2018. Review.

10.

The Influence of DAT1, COMT, and BDNF Genetic Polymorphisms on Total and Subregional Hippocampal Volumes in Early Onset Heavy Cannabis Users.

Batalla A, Lorenzetti V, Chye Y, Yücel M, Soriano-Mas C, Bhattacharyya S, Torrens M, Crippa JAS, Martín-Santos R.

Cannabis Cannabinoid Res. 2018 Feb 1;3(1):1-10. doi: 10.1089/can.2017.0021. eCollection 2018.

11.

Practical considerations in medical cannabis administration and dosing.

MacCallum CA, Russo EB.

Eur J Intern Med. 2018 Mar;49:12-19. doi: 10.1016/j.ejim.2018.01.004. Epub 2018 Jan 4. Review.

PMID:
29307505
12.

GPR55: A therapeutic target for Parkinson's disease?

Celorrio M, Rojo-Bustamante E, Fernández-Suárez D, Sáez E, Estella-Hermoso de Mendoza A, Müller CE, Ramírez MJ, Oyarzábal J, Franco R, Aymerich MS.

Neuropharmacology. 2017 Oct;125:319-332. doi: 10.1016/j.neuropharm.2017.08.017. Epub 2017 Aug 12.

PMID:
28807673
13.

GPR3 and GPR6, novel molecular targets for cannabidiol.

Laun AS, Song ZH.

Biochem Biophys Res Commun. 2017 Aug 12;490(1):17-21. doi: 10.1016/j.bbrc.2017.05.165. Epub 2017 May 29.

PMID:
28571738
14.

Neurological Aspects of Medical Use of Cannabidiol.

Mannucci C, Navarra M, Calapai F, Spagnolo EV, Busardò FP, Cas RD, Ippolito FM, Calapai G.

CNS Neurol Disord Drug Targets. 2017;16(5):541-553. doi: 10.2174/1871527316666170413114210. Review.

PMID:
28412918
15.

Cannabinoids therapeutic use: what is our current understanding following the introduction of THC, THC:CBD oromucosal spray and others?

Maccarrone M, Maldonado R, Casas M, Henze T, Centonze D.

Expert Rev Clin Pharmacol. 2017 Apr;10(4):443-455. doi: 10.1080/17512433.2017.1292849. Epub 2017 Feb 28. Review.

PMID:
28276775
16.

Cannabidiol Prevents Motor and Cognitive Impairments Induced by Reserpine in Rats.

Peres FF, Levin R, Suiama MA, Diana MC, Gouvêa DA, Almeida V, Santos CM, Lungato L, Zuardi AW, Hallak JE, Crippa JA, Vânia D, Silva RH, Abílio VC.

Front Pharmacol. 2016 Sep 28;7:343. eCollection 2016.

17.
18.

Endocannabinoid System: A Multi-Facet Therapeutic Target.

Kaur R, Ambwani SR, Singh S.

Curr Clin Pharmacol. 2016;11(2):110-7. Review.

PMID:
27086601
19.

The neuroprotection of cannabidiol against MPP⁺-induced toxicity in PC12 cells involves trkA receptors, upregulation of axonal and synaptic proteins, neuritogenesis, and might be relevant to Parkinson's disease.

Santos NA, Martins NM, Sisti FM, Fernandes LS, Ferreira RS, Queiroz RH, Santos AC.

Toxicol In Vitro. 2015 Dec 25;30(1 Pt B):231-40. doi: 10.1016/j.tiv.2015.11.004. Epub 2015 Nov 7.

20.

[Cannabinoids in neurology--Brazilian Academy of Neurology].

Brucki SM, Frota NA, Schestatsky P, Souza AH, Carvalho VN, Manreza ML, Mendes MF, Comini-Frota E, Vasconcelos C, Tumas V, Ferraz HB, Barbosa E, Jurno ME.

Arq Neuropsiquiatr. 2015 Apr;73(4):371-4. doi: 10.1590/0004-282X20150041. Epub 2015 Apr 1. Portuguese.

Supplemental Content

Loading ...
Support Center